SHARE
Vitae Pharmaceuticals, NASDAQ:VTAE, VTAE

Shares of Pernix Therapeutics Holdings Inc (NASDAQ:PTX) ended Wednesday session in red amid volatile trading. The shares closed down -0.013 points or -2.25% at $0.562 with 892,836 shares getting traded. Post opening the session at $0.56, the shares hit an intraday low of $0.55 and an intraday high of $0.58 and the price vacillated in this range throughout the day. The company has a market cap of $47.18 million and the numbers of outstanding shares have been calculated to be 85.12 million shares.

Pernix Therapeutics Holdings Inc (PTX) announced the distribution of TREXIMET® (sumatriptan and naproxen sodium) 10/60 mg to wholesalers has begun.  TREXIMET 10/60 mg is indicated for use in pediatric patients 12 years of age and older for the acute treatment of migraine with or without aura.  TREXIMET received U.S. Food and Drug Administration (FDA) approval for use in the pediatric population 12 years of age and older in May 2015; however, this formulation just recently became available due to manufacturing delays. The Company expects to begin focused product promotion activities in early Q4 2016.

“We are pleased to make TREXIMET available for pediatric patients,” said John Sedor, Chairman and CEO of Pernix Therapeutics.  “Pediatric migraine sufferers have long represented an underserved patient population,” continued Mr. Sedor. “TREXIMET has the potential to address a significant treatment void for pediatric patients.”

Shares of Novartis AG (ADR) (NYSE:NVS) ended Wednesday session in red amid volatile trading. The shares closed down -0.44 points or -0.57% at $76.37 with 4.07 million shares getting traded. Post opening the session at $75.85, the shares hit an intraday low of $75.59 and an intraday high of $76.64 and the price vacillated in this range throughout the day. The company has a market cap of $199.71 billion and the numbers of outstanding shares have been calculated to be 2.38 billion shares.

Novartis AG (ADR) (NVS) develops, manufactures, and markets a range of healthcare products worldwide. It operates through three segments: Pharmaceuticals, Alcon, and Sandoz. The Pharmaceuticals segment offers patented prescription medicines for oncology, neuroscience, retina, immunology and dermatology, respiratory, cardio-metabolic, established medicines, and cell and gene therapies. The Alcon segment provides eye care products, including ophthalmic surgical equipment, instruments, disposable products, and intraocular lenses; medicines to treat chronic and acute diseases of the eye, and over-the-counter medicines for the eye; and contact lenses and lens care products.

 

 

 

LEAVE A REPLY

Please enter your comment!
Please enter your name here